Free Trial
NASDAQ:TPST

Tempest Therapeutics (TPST) Stock Price, News & Analysis

Tempest Therapeutics logo
$10.02 +0.67 (+7.17%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$10.02 0.00 (0.00%)
As of 08/22/2025 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Tempest Therapeutics Stock (NASDAQ:TPST)

Key Stats

Today's Range
$9.35
$10.10
50-Day Range
$6.25
$10.53
52-Week Range
$5.33
$20.67
Volume
42,739 shs
Average Volume
108,739 shs
Market Capitalization
$44.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.00
Consensus Rating
Moderate Buy

Company Overview

Tempest Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
24th Percentile Overall Score

TPST MarketRank™: 

Tempest Therapeutics scored higher than 24% of companies evaluated by MarketBeat, and ranked 846th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Tempest Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Tempest Therapeutics has received no research coverage in the past 90 days.

  • Read more about Tempest Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Tempest Therapeutics are expected to grow in the coming year, from ($1.39) to ($1.05) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Tempest Therapeutics is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Tempest Therapeutics is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Tempest Therapeutics has a P/B Ratio of 4.55. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Tempest Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    5.72% of the float of Tempest Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Tempest Therapeutics has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Tempest Therapeutics has recently increased by 16.11%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Tempest Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Tempest Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    5.72% of the float of Tempest Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Tempest Therapeutics has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Tempest Therapeutics has recently increased by 16.11%, indicating that investor sentiment is decreasing significantly.
  • Search Interest

    Only 2 people have searched for TPST on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Tempest Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.70% of the stock of Tempest Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 22.52% of the stock of Tempest Therapeutics is held by institutions.

  • Read more about Tempest Therapeutics' insider trading history.
Receive TPST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tempest Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TPST Stock News Headlines

He Called Nvidia at $1.10. Now, He Says THIS Stock Will…
The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvidia at $1.10 reveals AI’s Next Magnificent Seven… including one stock he says could become America’s next trillion-dollar giant.tc pixel
See More Headlines

TPST Stock Analysis - Frequently Asked Questions

Tempest Therapeutics' stock was trading at $10.8485 at the beginning of the year. Since then, TPST stock has decreased by 7.6% and is now trading at $10.02.

Tempest Therapeutics, Inc. (NASDAQ:TPST) posted its quarterly earnings results on Monday, August, 11th. The company reported ($2.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.23) by $1.16.

Tempest Therapeutics shares reverse split on Friday, June 25th 2021.The 1-15 reverse split was announced on Friday, June 25th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 28th 2021. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Tempest Therapeutics' top institutional investors include Versant Venture Management LLC (7.33%), Geode Capital Management LLC (0.94%), Group One Trading LLC and Belvedere Trading LLC. Insiders that own company stock include Versant Venture Capital Vi, L, Stephen R Brady, Justin Trojanowski and Samuel Whiting.
View institutional ownership trends
.

Shares of TPST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Tempest Therapeutics investors own include Meta Platforms (META), Cloudflare (NET), NVIDIA (NVDA), Snowflake (SNOW), Tesla (TSLA), Intel (INTC) and Pfizer (PFE).

Company Calendar

Last Earnings
8/11/2025
Today
8/22/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:TPST
CIK
1544227
Fax
N/A
Employees
20
Year Founded
2012

Price Target and Rating

High Price Target
$65.00
Low Price Target
$9.00
Potential Upside/Downside
+199.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($14.59)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$41.84 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-334.76%
Return on Assets
-130.63%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.12
Quick Ratio
2.11

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.20 per share
Price / Book
4.55

Miscellaneous

Outstanding Shares
4,440,000
Free Float
4,231,000
Market Cap
$44.49 million
Optionable
Optionable
Beta
-1.93

Social Links

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:TPST) was last updated on 8/23/2025 by MarketBeat.com Staff
From Our Partners